How much profit has Elan made this year?
Elan has made 3.59 B JPY this year.
Elan Net Income 2025
Elan Net Income
3.59 B JPY
Ticker
6099.T
ISIN
JP3167680002
WKN
A12C13
In 2025, Elan's profit amounted to 3.59 B JPY, a 24.63% increase from the 2.88 B JPY profit recorded in the previous year.
The Elan Net Income history
| YEAR | NET INCOME (undefined JPY) |
|---|---|
| 2026e | 4.35 |
| 2025e | 3.59 |
| 2024e | 2.88 |
| 2023 | 2.52 |
| 2022 | 2.08 |
| 2021 | 1.91 |
| 2020 | 1.45 |
| 2019 | 0.99 |
| 2018 | 0.87 |
| 2017 | 0.66 |
| 2016 | 0.5 |
| 2015 | 0.36 |
| 2014 | 0.26 |
| 2013 | 0.25 |
| 2012 | 0.19 |
Elan Revenue, EBIT, Net Income JP3167680002 · A12C13
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Elan, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Elan from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Elan’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Elan. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Elan’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Elan’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Elan’s growth potential.
Elan Revenue, EBIT and net profit per share
| Date | Elan Revenue | Elan EBIT | Elan Net Income |
|---|---|---|---|
| 2026e | 62.62 B undefined | 0 undefined | 4.35 B undefined |
| 2025e | 55.55 B undefined | 0 undefined | 3.59 B undefined |
| 2024e | 47.97 B undefined | 0 undefined | 2.88 B undefined |
| 2023 | 41.43 B undefined | 3.67 B undefined | 2.52 B undefined |
| 2022 | 36.26 B undefined | 3.39 B undefined | 2.08 B undefined |
| 2021 | 31.64 B undefined | 2.8 B undefined | 1.91 B undefined |
| 2020 | 26.06 B undefined | 2.07 B undefined | 1.45 B undefined |
| 2019 | 21.52 B undefined | 1.49 B undefined | 989.6 M undefined |
| 2018 | 18.59 B undefined | 1.28 B undefined | 865.41 M undefined |
| 2017 | 15.47 B undefined | 912.93 M undefined | 657.73 M undefined |
| 2016 | 11.41 B undefined | 736.07 M undefined | 500.67 M undefined |
| 2015 | 9.01 B undefined | 588.49 M undefined | 363.05 M undefined |
| 2014 | 7.46 B undefined | 434 M undefined | 259 M undefined |
| 2013 | 6.03 B undefined | 403 M undefined | 248 M undefined |
| 2012 | 4.6 B undefined | 306 M undefined | 185 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2012 | 4.6 B JPY | 306 M JPY | 185 M JPY |
| 2013 | 6.03 B JPY | 403 M JPY | 248 M JPY |
| 2014 | 7.46 B JPY | 434 M JPY | 259 M JPY |
| 2015 | 9.01 B JPY | 588.49 M JPY | 363.05 M JPY |
| 2016 | 11.41 B JPY | 736.07 M JPY | 500.67 M JPY |
| 2017 | 15.47 B JPY | 912.93 M JPY | 657.73 M JPY |
| 2018 | 18.59 B JPY | 1.28 B JPY | 865.41 M JPY |
| 2019 | 21.52 B JPY | 1.49 B JPY | 989.6 M JPY |
| 2020 | 26.06 B JPY | 2.07 B JPY | 1.45 B JPY |
| 2021 | 31.64 B JPY | 2.8 B JPY | 1.91 B JPY |
| 2022 | 36.26 B JPY | 3.39 B JPY | 2.08 B JPY |
| 2023 | 41.43 B JPY | 3.67 B JPY | 2.52 B JPY |
| 2024e | 47.97 B JPY | 0 JPY | 2.88 B JPY |
| 2025e | 55.55 B JPY | 0 JPY | 3.59 B JPY |
| 2026e | 62.62 B JPY | 0 JPY | 4.35 B JPY |
Elan stock margins JP3167680002 · A12C13
The Elan margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Elan. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Elan.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Elan's sales revenue. A higher gross margin percentage indicates that the Elan retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Elan's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Elan's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Elan's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Elan. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Elan's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Elan Margin History
| Elan Gross margin | Elan Profit margin | Elan EBIT margin | Elan Profit margin |
|---|---|---|---|
| 2026e | 23.54 % | 0 % | 6.95 % |
| 2025e | 23.54 % | 0 % | 6.47 % |
| 2024e | 23.54 % | 0 % | 6.01 % |
| 2023 | 23.54 % | 8.85 % | 6.08 % |
| 2022 | 24.89 % | 9.35 % | 5.74 % |
| 2021 | 24.9 % | 8.85 % | 6.02 % |
| 2020 | 25.19 % | 7.94 % | 5.55 % |
| 2019 | 25.44 % | 6.94 % | 4.6 % |
| 2018 | 25.97 % | 6.88 % | 4.66 % |
| 2017 | 25.85 % | 5.9 % | 4.25 % |
| 2016 | 26.55 % | 6.45 % | 4.39 % |
| 2015 | 27.65 % | 6.53 % | 4.03 % |
| 2014 | 27.53 % | 5.81 % | 3.47 % |
| 2013 | 27.47 % | 6.69 % | 4.12 % |
| 2012 | 27.39 % | 6.65 % | 4.02 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2012 | 27.39 % | 6.65 % | 4.02 % |
| 2013 | 27.47 % | 6.69 % | 4.12 % |
| 2014 | 27.53 % | 5.81 % | 3.47 % |
| 2015 | 27.65 % | 6.53 % | 4.03 % |
| 2016 | 26.55 % | 6.45 % | 4.39 % |
| 2017 | 25.85 % | 5.9 % | 4.25 % |
| 2018 | 25.97 % | 6.88 % | 4.66 % |
| 2019 | 25.44 % | 6.94 % | 4.6 % |
| 2020 | 25.19 % | 7.94 % | 5.55 % |
| 2021 | 24.9 % | 8.85 % | 6.02 % |
| 2022 | 24.89 % | 9.35 % | 5.74 % |
| 2023 | 23.54 % | 8.85 % | 6.08 % |
| 2024e | 23.54 % | 0 % | 6.01 % |
| 2025e | 23.54 % | 0 % | 6.47 % |
| 2026e | 23.54 % | 0 % | 6.95 % |
Elan Aktienanalyse
What does Elan do?
Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Elan's Profit Margins
The profit margins of Elan represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Elan's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Elan's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Elan's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Elan’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Elan stock
How has the profit developed compared to last year?
The profit has increased by 24.63% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Elan publish its earnings?
Elan publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Elan?
The profits of Elan are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Elan?
You can learn more about the earnings of Elan by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Elan pay?
Over the past 12 months, Elan paid a dividend of 13 JPY . This corresponds to a dividend yield of about 1.77 %. For the coming 12 months, Elan is expected to pay a dividend of 15.1 JPY.
What is the dividend yield of Elan?
The current dividend yield of Elan is 1.77 %.
When does Elan pay dividends?
Elan pays a quarterly dividend. This is distributed in the months of January, January, January, January.
How secure is the dividend of Elan?
Elan paid dividends every year for the past 13 years.
What is the dividend of Elan?
For the upcoming 12 months, dividends amounting to 15.1 JPY are expected. This corresponds to a dividend yield of 2.05 %.
In which sector is Elan located?
Elan is assigned to the 'Health' sector.
Wann musste ich die Aktien von Elan kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Elan from 3/1/2025 amounting to 14 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.
When did Elan pay the last dividend?
The last dividend was paid out on 3/1/2025.
What was the dividend of Elan in the year 2024?
In the year 2024, Elan distributed 13 JPY as dividends.
In which currency does Elan pay out the dividend?
The dividends of Elan are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Elan
Our stock analysis for Elan Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Elan Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
